J Korean Ophthalmol Soc.  2009 Sep;50(9):1404-1408. 10.3341/jkos.2009.50.9.1404.

Effect of Bevacizumab on Survival and Production of Nitric Oxide in Trabecular Meshwork Cells

• Kim SH
• Kim JW

• KMID: 2212625
• DOI: http://doi.org/10.3341/jkos.2009.50.9.1404

Abstract

PURPOSE
To investigate the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), on the survival and production of nitric oxide (NO) in human trabecular meshwork cells (HTMC). METHODS: Primarily cultured HTMC were exposed to 0, 0.25, 1.0, and 2.5 mg/ml bevacizumab for 24 hours. Cellular survival and production of NO were assessed by MTT assay and Griess assay, respectively. RESULTS: Bevacizumab did not affect the cellular survival at low concentrations but decreased cellular survival significantly at high concentrations (>1.0 mg/ml) accompanied with increased NO production. CONCLUSIONS: High concentrations of bevacizumab may be toxic to HTMC.

Keyword

Bevacizumab; Nitric oxide; Trabecular meshwork cells

MeSH Terms

Antibodies, Monoclonal, Humanized
Humans
Nitric Oxide
Trabecular Meshwork
Vascular Endothelial Growth Factor A
Bevacizumab
Antibodies, Monoclonal, Humanized
Nitric Oxide
Vascular Endothelial Growth Factor A